Feasibility and Safety of Robotic Excision of Ipsilateral Retroperitoneal Recurrence After Nephrectomy for Renal Cell Carcinoma


      To determine feasibility and safety of robotic excision of local ipsilateral recurrences after nephrectomy for renal cell carcinoma (RCC). Surgical resection is an option for treatment of low burden locally recurrent RCC, potentially delaying the use of systemic therapy. This has historically been performed by open technique, which can impart significant morbidity. We present our experience with robotic excision.


      We reviewed our institutional experience of patients with surgically excised RCC who underwent robotic excision of ipsilateral retroperitoneal recurrence in 2015-2018. Demographics and clinicopathological variables, including operative and postoperative outcomes, were examined.


      Twelve robotic excisions of ipsilateral local recurrences were performed in our hospital in 2015-2018. Mean age was 65.48 years (± standard deviation, SD: 9.51), 10 patients were male, and mean BMI 34.75 kg/m2 (± 6.71). Nine patients recurred after radical nephrectomy, and 3 after partial nephrectomy. Mean size of recurrence was 2.97 cm (±1.69). Mean anesthesia time, EBL, and LOS were 213 minutes (± 38.92), 152 mL (± 130.75), and 43 hours (± 12.64), respectively. All surgical margins were negative. No surgical complications were reported. Median follow-up was 19.0 months [interquartile range, IQR 12.7-30.0]. Five patients out of 12 recurred following robotic excision, these were treated with either systemic therapy, radiation, or palliative surgeries. Mean time for subsequent recurrence was 26.5 months.


      In this small case series, robotic excision of ipsilateral RCC retroperitoneal recurrence appears safe, technically feasible, and oncologically sound in expert hands and carefully selected patients.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2020.
        CA Cancer J Clin. 2020; 70: 7-30
        • Itano N.B.
        • Blute M.L.
        • Spotts B.
        • Zincke H.
        Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy.
        J Urol. 2000; 164: 322-325
        • Schrodter S.
        • Hakenberg O.W.
        • Manseck A.
        • Leike S.
        • Wirth M.P.
        Outcome of surgical treatment of isolated local recurrence after radical nephrectomy for renal cell carcinoma.
        J Urol. 2002; 167: 1630-1633
        • Pantuck A.J.
        • Zisman A.
        • Belldegrun A.S.
        The changing natural history of renal cell carcinoma.
        J Urol. 2001; 166: 1611-1623
        • Thomas A.Z.
        • Adibi M.
        • Borregales L.D.
        • et al.
        Surgical management of local retroperitoneal recurrence of renal cell carcinoma after radical nephrectomy.
        J Urol. 2015; 194: 316-322
        • Sandhu S.S.
        • Symes A.
        • A'Hern R.
        • et al.
        Surgical excision of isolated renal-bed recurrence after radical nephrectomy for renal cell carcinoma.
        BJU Int. 2005; 95: 522-525
        • Russell C.M.
        • Lue K.
        • Fisher J.
        • et al.
        Oncological control associated with surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma.
        BJU Int. 2016; 117: E60-E66
        • Nakada S.Y.
        • Johnson D.B.
        • Hahnfield L.
        • Jarrard D.F.
        Resection of isolated fossa recurrence of renal-cell carcinoma after nephrectomy using hand-assisted laparoscopy.
        J Endourol. 2002; 16: 687-688
        • Bandi G.
        • Wen C.C.
        • Moon T.D.
        • Nakada S.Y.
        Single center preliminary experience with hand-assisted laparoscopic resection of isolated renal cell carcinoma fossa recurrences.
        Urology. 2008; 71 (discussion 499-500): 495-499
        • Yohannan J.
        • Feng T.
        • Berkowitz J.
        • et al.
        Laparoscopic resection of local recurrence after previous radical nephrectomy for clinically localized renal-cell carcinoma: perioperative outcomes and initial observations.
        J Endourol. 2010; 24: 1609-1612
        • Sanli O.
        • Erdem S.
        • Tefik T.
        • et al.
        Laparoscopic excision of local recurrence of renal cell carcinoma.
        Jsls. 2012; 16: 597-605
        • Gilbert D.
        • Abaza R.
        Robotic excision of recurrent renal cell carcinomas with laparoscopic ultrasound assistance.
        Urology. 2015; 85: 1206-1210
        • Nelson R.J.
        • Reese J.H.
        • Babbar P.
        • Kaouk J.H.
        Robotic retrocaval metastasectomy after an ipsilateral radical nephrectomy.
        Urology. 2017; 107: 270
        • Heng D.Y.
        • Xie W.
        • Regan M.M.
        • et al.
        External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.
        Lancet Oncol. 2013; 14: 141-148
        • Romeo A.
        • Garcia Marchinena P.
        • Jurado A.M.
        • Gueglio G.
        Renal fossa recurrence after radical nephrectomy: current management, and oncological outcomes.
        Urol Oncol. 2020; 38: 42.e7-42.e12
        • Dekernion J.B.
        • Ramming K.P.
        • Smith R.B.
        The natural history of metastatic renal cell carcinoma: a computer analysis.
        J Urol. 1978; 120: 148-152
        • Motzer R.J.
        • Tannir N.M.
        • McDermott D.F.
        • et al.
        Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma.
        N Engl J Med. 2018; 378: 1277-1290
        • Rini B.I.
        • Plimack E.R.
        • Stus V.
        • et al.
        Pembrolizumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma.
        N Engl J Med. 2019; 380: 1116-1127
        • Tannir N.M.
        • McDermott D.F.
        • Escudier B.
        • et al.
        Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
        J Clinl Oncol. 2020; 38 (609-609)